SuperworthBeOne Medicines EPS ONC
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- $0.43
- Latest quarter, Q2 FY26
- $0.16
- +167% on a year earlier
- Fiscal year 2025
- $0.18
BeOne Medicines' earnings per share was $0.43 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.16, up 167% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.18 | n/a |
| FY2024 | −$0.48 | n/a |
| FY2023 | −$0.66 | n/a |
| FY2022 | −$1.49 | n/a |
| FY2021 | −$1.18 | n/a |
| FY2020 | −$1.46 | n/a |
| FY2019 | −$1.21 | n/a |
| FY2018 | −$0.92 | n/a |
| FY2017 | −$0.19 | n/a |
| FY2016 | −$0.29 | n/a |
| FY2015 | −$0.49 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.16 | +167% | $0.43 | |
| Q1 FY26 | $0.15 | n/a | $0.33 | |
| Q4 FY25 | $0.04 | n/a | $0.18 | |
| Q3 FY25 | $0.08 | n/a | $0.03 | |
| Q2 FY25 | $0.06 | n/a | −$0.14 | |
| Q1 FY25 | $0.00 | n/a | −$0.29 | |
| Q4 FY24 | −$0.11 | n/a | −$0.48 | |
| Q3 FY24 | −$0.09 | −160% | −$0.64 | |
| Q2 FY24 | −$0.09 | n/a | −$0.40 | |
| Q1 FY24 | −$0.19 | n/a | −$0.59 | |
| Q4 FY23 | −$0.27 | n/a | −$0.66 | |
| Q3 FY23 | $0.15 | n/a | −$0.72 |
Against its peers
Companies in Biotechnology nearest BeOne Medicines' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ONCBeOne Medicines | $0.43 | |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| INCYIncyte | $7.85 | +78% a year |
| REGNRegeneron Pharmaceuticals | $40.44 | +2% a year |
| EXELExelixis | $3.18 | +53% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| VRTXVertex Pharmaceuticals | $17.18 | +23% a year |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| RGENRepligen | $0.73 | |
| Peer median | $6.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on BeOne Medicines
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.